
|Videos|July 4, 2022
Prostate cancer disparities have deepened since USPSTF negative screening recommendation
Author(s)Urology Times staff
“Patients who really need to be screened are not getting screened,” says Ram Pathak, MD.
Advertisement
In this video, Ram Pathak, MD, an assistant professor at Mayo Clinic, discusses how the United States Preventative Services Task Force (USPSTF) grade D recommendation against PSA screening has resulted in a disproportionate increase in the incidence of metastatic prostate cancer among minority populations at screening.
At the 2022 AUA Annual Meeting, Pathak shared the abstract, “Racial and ethnic disparities magnified after USPSTF category D recommendation for PSA screening.”
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA updates in urology: May 2026
4
FDA approves cefepime and zidebactam for complicated UTI
5











